^
Association details:
| Biomarker: | DLL3 expression |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma
Published date:
07/11/2022
Excerpt:
We first tested the efficacy of Rova-T in four neuroblastoma PDX models using a conventional design of 8–10 mice per arm. In the PDX array, all four of these models had robust DLL3 expression...There was a clear dose–response effect, and all models showed some or significant evidence of antitumor activity at a single 0.6 mg/kg dose (i.e., one injection) of Rova-T...
DOI:
https://doi.org/10.1158/2767-9764.CRC-22-0137
